Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

200
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
200
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

128
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
128
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

141
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
141
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

208
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
208
Measurement of Bioavailability: Pharmacokinetic Methods01:30

Measurement of Bioavailability: Pharmacokinetic Methods

219
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
219
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

129
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
129

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

State Insulin Out-of-Pocket Cap Policies and Estimated Eligible Populations in the United States, 2019-2026.

Diabetes care·2026
Same author

Access to GLP-1s for Medicare Beneficiaries - A Bridge to Nowhere?

The New England journal of medicine·2026
Same author

Access to Specialty Cancer Care and Plan Disenrollment Among Medicare Beneficiaries.

JAMA network open·2026
Same author

Pharmacoequity and the Promise of GLP-1 Therapies in Cardiovascular Disease.

Circulation·2026
Same author

Patient-Reported Experiences With Viewing and Understanding Test Results in Patient Portals: Cross-Sectional Survey Analysis.

Journal of medical Internet research·2026
Same author

Resetting the Evidence Bar for New Anticancer Drug Approvals.

JAMA network open·2026
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
Same journal

FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

JAMA·2026
Same journal

HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

JAMA·2026
Same journal

US Dietary Supplement Use Increasing, Especially in Older Adults.

JAMA·2026
Same journal

Heat Stress From Climate Change Surges Globally.

JAMA·2026
Same journal

Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

JAMA·2026
See all related articles

Related Experiment Video

Updated: Jan 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Real-Time Benefit Tools for Drug Prices

Jordan Everson1,2, Mark E Frisse2, Stacie B Dusetzina1

  • 1School of Medicine, Department of Health Policy, Vanderbilt University, Nashville, Tennessee.

JAMA
|October 26, 2019
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.7K
Measuring Real-time Drug Response in Organotypic Tumor Tissue Slices
08:27

Measuring Real-time Drug Response in Organotypic Tumor Tissue Slices

Published on: May 2, 2020

12.2K

Related Experiment Videos

Last Updated: Jan 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.7K
Measuring Real-time Drug Response in Organotypic Tumor Tissue Slices
08:27

Measuring Real-time Drug Response in Organotypic Tumor Tissue Slices

Published on: May 2, 2020

12.2K